Answers are grounded in this paper and cite their sources.
, BRD inhibition led to a robust anti-inflammatory effect, decreasing cytokine secretion (including IL-1β, MCP-1, IL-1α, and IL-6) and preventing immune cell migration to inflamed lymph nodes in a TNF-α-stimulated murine model. Our findings highlight CBP/EP300-BRDs as promising targets for autoimmune therapy, with these non-cytotoxic inhibitors offering a potential complementary approach for RA and other TNF-α-mediated inflammatory conditions.
No takes yet. Share an insight, caveat, or question.
Gosselé et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: